Aktis Oncology (NASDAQ:AKTS) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

Aktis Oncology (NASDAQ:AKTS)’s stock price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $23.59 and traded as high as $25.22. Aktis Oncology shares last traded at $24.63, with a volume of 244,597 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AKTS. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. HC Wainwright boosted their price objective on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Raymond James Financial initiated coverage on Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their target price on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.60.

Aktis Oncology Stock Performance

The stock has a fifty day moving average price of $23.59. The company has a market capitalization of $1.32 billion and a price-to-earnings ratio of -64.82.

Aktis Oncology (NASDAQ:AKTS) last released its earnings results on Monday, May 11th. The technology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The business had revenue of $3.23 million for the quarter, compared to analysts’ expectations of $2.23 million. As a group, research analysts predict that Aktis Oncology will post -1.64 earnings per share for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.